Cargando…

Increased Vulnerability of Human Ventricle to Re-entrant Excitation in hERG-linked Variant 1 Short QT Syndrome

The short QT syndrome (SQTS) is a genetically heterogeneous condition characterized by abbreviated QT intervals and an increased susceptibility to arrhythmia and sudden death. This simulation study identifies arrhythmogenic mechanisms in the rapid-delayed rectifier K(+) current (I(Kr))-linked SQT1 v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adeniran, Ismail, McPate, Mark J., Witchel, Harry J., Hancox, Jules C., Zhang, Henggui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240585/ https://www.ncbi.nlm.nih.gov/pubmed/22194679 http://dx.doi.org/10.1371/journal.pcbi.1002313

Ejemplares similares

hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome
por: McPate, M.J., et al.
Publicado: (2009)

Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles
por: Whittaker, Dominic G., et al.
Publicado: (2017)

In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome
por: Whittaker, Dominic G., et al.
Publicado: (2019)

In silico investigation of the short QT syndrome, using human ventricle models incorporating electromechanical coupling
por: Adeniran, Ismail, et al.
Publicado: (2013)

Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG ‘hotspot’ mutation
por: Du, Chunyun, et al.
Publicado: (2022)

Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K(+) Channel
por: El Harchi, Aziza, et al.
Publicado: (2012)

Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome
por: Butler, Andrew, et al.
Publicado: (2019)

An Update on the Structure of hERG
por: Butler, Andrew, et al.
Publicado: (2020)

Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking
por: Zhang, Yihong, et al.
Publicado: (2016)

Electrophysiological characterization of the modified hERG(T) potassium channel used to obtain the first cryo‐EM hERG structure
por: Zhang, Yihong, et al.
Publicado: (2020)

Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome
por: Butler, Andrew, et al.
Publicado: (2018)

Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition
por: Du, Chunyun, et al.
Publicado: (2013)

Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome
por: El Harchi, Aziza, et al.
Publicado: (2009)

Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin
por: Duncan, R.S., et al.
Publicado: (2007)

hERG channel function: beyond long QT
por: Babcock, Joseph J, et al.
Publicado: (2013)

The Basis for Low-affinity hERG Potassium Channel Block by Sotalol
por: Zhang, Yi Hong, et al.
Publicado: (2017)

In silico investigation of a KCNQ1 mutation associated with short QT syndrome
por: Adeniran, Ismail, et al.
Publicado: (2017)

Serine mutation of a conserved threonine in the hERG K(+) channel S6-pore region leads to loss-of-function through trafficking impairment
por: Al-Moubarak, Ehab, et al.
Publicado: (2020)

hERG1a N-terminal eag domain–containing polypeptides regulate homomeric hERG1b and heteromeric hERG1a/hERG1b channels: A possible mechanism for long QT syndrome
por: Trudeau, Matthew C., et al.
Publicado: (2011)

Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide
por: Melgari, Dario, et al.
Publicado: (2015)

Voltage Sensor Gating Charge Transfer in a hERG Potassium Channel Model
por: Colenso, Charlotte K., et al.
Publicado: (2014)

Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue
por: Helliwell, Matthew V., et al.
Publicado: (2023)

Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome
por: Cheng, Hongwei, et al.
Publicado: (2019)

Rapid Characterization of hERG Channel Kinetics II: Temperature Dependence
por: Lei, Chon Lok, et al.
Publicado: (2019)

Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration
por: Melgari, Dario, et al.
Publicado: (2014)

Identification of a proton sensor that regulates conductance and open time of single hERG channels
por: Wilson, Stacey L., et al.
Publicado: (2019)

The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine
por: El Harchi, Aziza, et al.
Publicado: (2020)

Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy
por: LI, GUOLIANG, et al.
Publicado: (2016)

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block
por: Tran, Phu N., et al.
Publicado: (2020)

Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant
por: Al-Moubarak, Ehab, et al.
Publicado: (2021)

The hERG K(+) channel S4 domain L532P mutation: Characterization at 37 °C
por: Zhang, Yi H., et al.
Publicado: (2011)

hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine
por: Melgari, Dario, et al.
Publicado: (2015)

Ranolazine inhibition of hERG potassium channels: Drug–pore interactions and reduced potency against inactivation mutants
por: Du, Chunyun, et al.
Publicado: (2014)

Structural implications of hERG K(+) channel block by a high-affinity minimally structured blocker
por: Helliwell, Matthew V., et al.
Publicado: (2018)

hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation
por: Chang, Yun, et al.
Publicado: (2021)

Pharmacological activation of the hERG K(+) channel for the management of the long QT syndrome: A review
por: El Harchi, Aziza, et al.
Publicado: (2022)

Evolutionary coupling analysis guides identification of mistrafficking-sensitive variants in cardiac K(+) channels: Validation with hERG
por: Zhang, Yihong, et al.
Publicado: (2022)

In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget
por: Al-Moubarak, Ehab, et al.
Publicado: (2021)

The electric heart of hERG
por: Islas, León D.
Publicado: (2013)

Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation
por: Aromolaran, Ademuyiwa S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_09e1dnr2khaequd8caffdh1g5c